News

We are proud to have been recognised by StartUp City Magazine as one of the most promising European Biotech startups in 2019!

Press release

Oblique Therapeutics has been recognized as one of the 15 most promising Biotech startups in Europe 2019, by StartUp City magazine

Gothenburg, Sweden, July 17, 2019 – Oblique Therapeutics, a Swedish biotech focusing on generating novel therapeutic antibodies towards severe diseases such as cancer and pain, has been honored as one of the most promising biotech startup in Europe 2019 by StartUp City magazine. An interview with the CEO, Owe Orwar is featured on the cover story of the BioTech special issue published this month.

StartUp City Magazine: “Oblique Therapeutics is uncovering medical breakthroughs in antibody therapeutics using its proporietary technology platform AbiprotTM ”. The AbiprotTM technology enables the development of antibodies against difficult-to-drug targets such as ion channels and certain G-protein-coupled receptors (GPCRs) that can translate into new effective treatment options for large groups of patients in need of new medicines.

“ It is an honor to receive this recognition, and we are devoted to continue on building and advancing our pipeline with new antibody therapeutics that matters to patients” says Owe Orwar, CEO

The article can be accessed from: Biotech-startup

For more information, please contact:
Owe Orwar, CEO
Email: owe@obliquet.com
About Oblique Therapeutics
Oblique Therapeutics is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer.  The company uses AbiprotTM, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises three in-house programs – two antibody candidates: aKRAS in advanced cancer, aTRPA1 in pain; and the small molecule OT-1096 in triple-negative breast cancer. In addition, there are three antibodies programs in collaboration with pharma. Oblique Therapeutics makes medicines that matter to patients. http://obliquet.com

We welcome our new owners

We would like to welcome our new international- as well as Scandinavian owners after closing this funding round.

New collaboration with Pharma

Oblique Therapeutics has entered into a collaboration agreement with a mid-sized Pharma for the development of the TRPV1 antibody.

BioEurope

Our CEO, Owe Orwar, and CSO, Carolina Trkulja, will be attending BioEurope in Copenhagen, 5-7 November, 2018